<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02963389</url>
  </required_header>
  <id_info>
    <org_study_id>DA3031_PNP_I</org_study_id>
    <nct_id>NCT02963389</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim in Pediatric Solid Tumor/Lymphoma Patients</brief_title>
  <official_title>A Phase I Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim After Single Administration in Pediatric Solid Tumor/Lymphoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <brief_summary>
    <textblock>
      This is an open-label, single ascending dose study to evaluate safety, tolerability, and
      pharmacokinetics/pharmacodynamics of Tripegfilgrastim in pediatric solid tumor/lymphoma
      patients
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 4, 2016</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK parameter</measure>
    <time_frame>Day 1(Hour 0) ~ Day 21</time_frame>
    <description>Time to reach Cmax of Tripegfilgrastim [Tmax]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter</measure>
    <time_frame>Day 1(Hour 0) ~ Day 21</time_frame>
    <description>Peak plasma concentration of Tripegfilgrastim [Cmax]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter</measure>
    <time_frame>Day 1(Hour 0) ~ Day 21</time_frame>
    <description>Area under the plasma concentration of Tripegfilgrastim versus time curve [AUC]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter</measure>
    <time_frame>Day 1(Hour 0) ~ Day 21</time_frame>
    <description>Half-life of Tripegfilgrastim [T1/2]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter</measure>
    <time_frame>Day 1(Hour 0) ~ Day 21</time_frame>
    <description>The lowest plasma concentration that Tripegfilgrastim reaches before the next dose is administered [Ctrough]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PD parameter</measure>
    <time_frame>Day 1(Hour 0) ~ Day 14</time_frame>
    <description>Peak plasma concentration of Absolute Neutrophil Count [ANCmax]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD parameter</measure>
    <time_frame>Day 1(Hour 0) ~ Day 14</time_frame>
    <description>Area under the plasma concentration of Absolute Neutrophil Count versus time curve [AUC(ANC)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD parameter</measure>
    <time_frame>Day 1(Hour 0) ~ Day 14</time_frame>
    <description>Time to reach Cmax of Absolute Neutrophil Count [Tmax(ANC)]</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Tripegfilgrastim 60ug/kg, &gt;=6 and &lt;12-year-old patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of Tripegfilgrastim 60ug/kg, S.C, 24hr after completion of chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tripegfilgrastim 60ug/kg, &gt;=12 and &lt;19-year-old patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of Tripegfilgrastim 60ug/kg, S.C, 24hr after completion of chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tripegfilgrastim 100ug/kg, &gt;=6 and &lt;12-year-old patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of Tripegfilgrastim 100ug/kg, S.C, 24hr after completion of chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tripegfilgrastim 100ug/kg, &gt;=12 and &lt;19-year-old patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of Tripegfilgrastim 100ug/kg, S.C, 24hr after completion of chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tripegfilgrastim</intervention_name>
    <arm_group_label>Tripegfilgrastim 60ug/kg, &gt;=6 and &lt;12-year-old patients</arm_group_label>
    <arm_group_label>Tripegfilgrastim 60ug/kg, &gt;=12 and &lt;19-year-old patients</arm_group_label>
    <arm_group_label>Tripegfilgrastim 100ug/kg, &gt;=6 and &lt;12-year-old patients</arm_group_label>
    <arm_group_label>Tripegfilgrastim 100ug/kg, &gt;=12 and &lt;19-year-old patients</arm_group_label>
    <other_name>DA-3031</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;=6 and &lt;19-year-old pediatrics with solid tumor/lymphoma

          -  Scheduled for chemotherapy requiring G-CSF support or having given an experience of
             ANC &lt; 0.5x10^9/L

          -  ANC &gt; 0.75x10^9/L, platelet &gt; 75x10^9/L

          -  ECOG performance status 0 or 1

        Exclusion Criteria:

          -  Patients with leukemia, myelodysplastic syndrome or uncontrolled infectious/nervous
             diseases

          -  History of allergy to filgrastim, pegfilgrastim or known hypersensitivity to E-coli
             derived proteins.

          -  Women who are pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hyoung Jin Kang, MD, PhD</last_name>
    <email>kanghj@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Che Ry Hong, MD</last_name>
    <email>cherryhong84@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>82</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyoung Jin Kang, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2016</study_first_submitted>
  <study_first_submitted_qc>November 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2016</study_first_posted>
  <last_update_submitted>May 26, 2017</last_update_submitted>
  <last_update_submitted_qc>May 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

